Minerva Neurosciences Net Income Growth & History (NERV)
Minerva Neurosciences's net income was −$293.4M for fiscal 2025.
View full Minerva Neurosciences company overviewMinerva Neurosciences annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$293.4M | −$294.9M | — |
| 2024 | 2024-12-31 | $1.4M | $31.4M | — |
| 2023 | 2023-12-31 | −$30.0M | $2.1M | — |
| 2022 | 2022-12-31 | −$32.1M | $17.8M | — |
| 2021 | 2021-12-31 | −$49.9M | −$51.8M | — |
| 2020 | 2020-12-31 | $1.9M | $74.1M | — |
| 2019 | 2019-12-31 | −$72.2M | −$22.0M | — |
| 2018 | 2018-12-31 | −$50.2M | −$18.6M | — |
| 2017 | 2017-12-31 | −$31.5M | −$477,835 | — |
| 2016 | 2016-12-31 | −$31.0M | −$4.0M | — |
| 2015 | 2015-12-31 | −$27.1M | $29.8M | — |
| 2014 | 2014-12-31 | −$56.9M | — | — |
Minerva Neurosciences quarterly net income
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $17.5M | $20.7M | — |
| Q1 2026 | 2026-03-31 | −$125.4M | −$121.7M | — |
| Q4 2025 | 2025-12-31 | −$283.7M | −$279.4M | — |
| Q3 2025 | 2025-09-30 | −$2.7M | −$25.3M | — |
| Q2 2025 | 2025-06-30 | −$3.3M | $5.0M | — |
| Q1 2025 | 2025-03-31 | −$3.8M | $4.8M | — |
| Q4 2024 | 2024-12-31 | −$4.3M | $4.8M | — |
| Q3 2024 | 2024-09-30 | $22.5M | $30.3M | — |
| Q2 2024 | 2024-06-30 | −$8.2M | −$2.0M | — |
| Q1 2024 | 2024-03-31 | −$8.6M | −$1.6M | — |
| Q4 2023 | 2023-12-31 | −$9.0M | −$2.3M | — |
| Q3 2023 | 2023-09-30 | −$7.8M | −$919,970 | — |
| Q2 2023 | 2023-06-30 | −$6.2M | $2.5M | — |
| Q1 2023 | 2023-03-31 | −$7.0M | $2.8M | — |
| Q4 2022 | 2022-12-31 | −$6.7M | $14.6M | — |
| Q3 2022 | 2022-09-30 | −$6.9M | $2.3M | — |
| Q2 2022 | 2022-06-30 | −$8.7M | $1.9M | — |
| Q1 2022 | 2022-03-31 | −$9.8M | −$959,696 | — |
| Q4 2021 | 2021-12-31 | −$21.3M | −$14.0M | — |
| Q3 2021 | 2021-09-30 | −$9.2M | −$1.1M | — |
| Q2 2021 | 2021-06-30 | −$10.6M | −$40.1M | — |
| Q1 2021 | 2021-03-31 | −$8.8M | $3.3M | — |
| Q4 2020 | 2020-12-31 | −$7.3M | $22.6M | — |
| Q3 2020 | 2020-09-30 | −$8.1M | $5.8M | — |
| Q2 2020 | 2020-06-30 | $29.5M | $42.0M | — |
| Q1 2020 | 2020-03-31 | −$12.2M | $3.7M | — |
| Q4 2019 | 2019-12-31 | −$29.9M | −$16.7M | — |
| Q3 2019 | 2019-09-30 | −$14.0M | −$1.9M | — |
| Q2 2019 | 2019-06-30 | −$12.5M | $53,000 | — |
| Q1 2019 | 2019-03-31 | −$15.8M | −$3.4M | — |
| Q4 2018 | 2018-12-31 | −$13.2M | −$13.4M | — |
| Q3 2018 | 2018-09-30 | −$12.0M | −$761,000 | — |
| Q2 2018 | 2018-06-30 | −$12.5M | −$2.7M | — |
| Q1 2018 | 2018-03-31 | −$12.4M | −$1.8M | — |
| Q4 2017 | 2017-12-31 | $162,000 | $9.6M | — |
| Q3 2017 | 2017-09-30 | −$11.3M | −$2.8M | — |
| Q2 2017 | 2017-06-30 | −$9.8M | −$4.6M | — |
| Q1 2017 | 2017-03-31 | −$10.6M | −$2.6M | — |
| Q4 2016 | 2016-12-31 | −$9.4M | −$965,000 | — |
| Q3 2016 | 2016-09-30 | −$8.4M | −$2.5M | — |
| Q2 2016 | 2016-06-30 | −$5.2M | $1.4M | — |
| Q1 2016 | 2016-03-31 | −$8.0M | −$1.9M | — |
| Q4 2015 | 2015-12-31 | −$8.4M | −$997,000 | — |
| Q3 2015 | 2015-09-30 | −$5.9M | $21.2M | — |
| Q2 2015 | 2015-06-30 | −$6.6M | $12.8M | — |
| Q1 2015 | 2015-03-31 | −$6.1M | −$3.2M | — |
| Q4 2014 | 2014-12-31 | −$7.4M | −$5.3M | — |
| Q3 2014 | 2014-09-30 | −$27.2M | −$26.7M | — |
| Q2 2014 | 2014-06-30 | −$19.4M | −$19.0M | — |
| Q1 2014 | 2014-03-31 | −$2.9M | −$2.7M | — |
| Q4 2013 | 2013-12-31 | −$2.1M | — | — |
| Q3 2013 | 2013-09-30 | −$488,000 | — | — |
| Q2 2013 | 2013-06-30 | −$376,000 | — | — |
| Q1 2013 | 2013-03-31 | −$271,000 | — | — |
Minerva Neurosciences net income trends
Over the last five fiscal years, Minerva Neurosciences's net income decreased from $1.9M to −$293.4M, a change of −$295.4M. The latest reported quarter, Q2 2026, shows $17.5M.
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Minerva Neurosciences source filings ↗